Quick answer
Isabella Cruz is a Regional Market Access Analyst for Asia-Pacific Region pharmaceutical intelligence editor on NovaPharmaNews, with 13 published articles covering NMPA regulatory actions, clinical development, and market-moving news. Isabella Cruz analyzes reimbursement policy, formulary pathways, and patient access trends across APAC health systems. In 9 years covering access strategy, she has focused on launch sequencing and evidence requirements by market.
About Isabella Cruz
Isabella Cruz analyzes reimbursement policy, formulary pathways, and patient access trends across APAC health systems. In 9 years covering access strategy, she has focused on launch sequencing and evidence requirements by market.
Coverage focus
Topics and beats Isabella covers across Asia-Pacific Region.
Explore related intelligence
Entity directories linked from this author's coverage.
- Global markets Cross-region command center
- Company directory Sponsor & marketer profiles
- Drug profiles INN & regulatory status
- Clinical trials hub Stage & therapy filters
- Pipeline programs R&D intelligence
- Patent landscape US & EP IP moats
- Event calendar Congress catalysts
- Regulatory reference Submission types & pathways
Articles by Isabella Cruz
FDA Approves Travere's FILSPARI for FSGS Treatment in Adults and Children 8+
Travere Therapeutics receives FDA approval for FILSPARI to reduce proteinuria in FSGS patients aged 8 and older, expanding rare kidney disease treatment options.
Axoft Raises $55M Series A to Advance Brain-Computer Interface Clinical Trials Globally
Axoft secures $55M Series A funding led by C.P. Group Innovation to advance bio-inspired brain-computer interface technology into global clinical trials.
Insilico Medicine's Rentosertib Inhalation Solution Receives IND Clearance for First AI-Driven Direct-to-Lung Clinical Trial
Insilico Medicine's AI-discovered Rentosertib inhalation solution gets IND clearance for direct-to-lung delivery, marking a milestone in AI drug development.
Yangtze River Pharmaceutical Group Quadruples International Revenue in 2025 Global Expansion
Yangtze River Pharmaceutical Group reports 4x international revenue growth, doubling global partnerships while exporting 100+ products to 40+ countries.
ANVISA risk-based inspection: What You Need to Know
Learn about ANVISA's risk-based inspection approach, crucial for maintaining drug safety and efficacy in the pharmaceutical industry.
HTA Outcomes Oncology Drugs: EU Regulation Impact on Germany, France, Italy
This article examines the effects of EU regulations on HTA outcomes for oncology drugs, focusing on implications for Germany, France, and Italy.
ANVISA Approves Trastuzumab Deruxtecan: What You Need to Know
Trastuzumab Deruxtecan has been approved by ANVISA for the treatment of HER2-positive breast cancer, offering new hope for patients and healthcare providers.
Aquestive Therapeutics Faces Class Action Lawsuit Over Anaphylm Drug Approval Timeline Claims
Investors file class action against Aquestive Therapeutics alleging misleading statements about Anaphylm sublingual film approval timeline and January 2026 PDUFA date.
ANVISA Approves Emtricitabine + Tenofovir Fumarate: Market Impact in Brazil
The recent ANVISA approval of Emtricitabine + Tenofovir Fumarate marks a pivotal moment for HIV treatment options in Brazil, influencing market dynamics.
MorphoSys' MINJUVI (Tafasitamab) Approved in Australia for Relapsed/Refractory Follicular Lymphoma
Australia approves MINJUVI (tafasitamab) as first chemotherapy-free dual-targeted immunotherapy for relapsed/refractory follicular lymphoma patients.
WuXi Biologics Receives South Korea GMP Certification for Bispecific Antibody Manufacturing
WuXi Biologics secures South Korea MFDS GMP certification for three facilities, enabling commercial manufacturing of bispecific antibody therapeutics.
Australia's TGA Updates Therapeutic Sunscreen Regulatory Framework for Enhanced Consumer Protection
Australia's TGA provides comprehensive guidance on therapeutic sunscreen regulation, covering application processes, market authorization, and compliance requirements.
FDA Approval Elarekig: What You Need to Know About TRD Treatment
Elarekig has received FDA approval for treating treatment-resistant depression (TRD), offering new hope for patients seeking effective solutions.
Frequently asked questions
Who writes NovaPharmaNews articles?
Each story is attributed to a named editor or analyst with a public author profile. Profiles list credentials, coverage focus, and every published article so readers and AI systems can verify expertise and trace claims to a accountable journalist.
How do I find more coverage from this author?
Scroll to the article archive on this page, or use the topic chips linked from the author’s specializations. The regional authors directory lists every active contributor in this edition.
How does author coverage connect to companies and pipeline data?
Articles link to company profiles, drug INN pages, clinical trials, and pipeline programs when entities are tagged. Use the intelligence spokes on each story or browse topic hubs from the author’s beat.